Bioequivalence Study of Klaribact 125mg/5ml, Suspension

NACompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 29, 2013

Primary Completion Date

July 8, 2013

Study Completion Date

October 25, 2013

Conditions
Healthy
Interventions
DRUG

Klaribact 125mg/5ml Suspension

one single 20 mL dose (500mg) of the test drug will be administered to the volunteers

DRUG

Klaricid 125mg/5ml Suspension

one single 20 mL dose (500mg) of the Reference drug will be administered to the volunteers

Trial Locations (1)

75270

Center for Bioequivalence Studies and clinical research (CBSCR), ICCBS, Karachi

All Listed Sponsors
collaborator

Merck (Pvt.) Limited, Pakistan

UNKNOWN

collaborator

Center for Bioequivalence Studies and Clinical Research (CBSCR), HEJ Research Institute of chemistry, University of Karachi

UNKNOWN

lead

University of Karachi

OTHER

NCT05340452 - Bioequivalence Study of Klaribact 125mg/5ml, Suspension | Biotech Hunter | Biotech Hunter